Codexis, Inc. (CDXS)
| Market Cap | 170.83M -37.9% |
| Revenue (ttm) | 77.68M +35.9% |
| Net Income | -30.72M |
| EPS | -0.34 |
| Shares Out | 109.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,244,545 |
| Open | 1.610 |
| Previous Close | 1.600 |
| Day's Range | 1.510 - 1.620 |
| 52-Week Range | 0.958 - 3.870 |
| Beta | 2.50 |
| Analysts | Buy |
| Price Target | 6.50 (+316.67%) |
| Earnings Date | Aug 11, 2026 |
About CDXS
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The co... [Read more]
Financial Performance
In 2025, Codexis's revenue was $70.39 million, an increase of 18.61% compared to the previous year's $59.35 million. Losses were -$43.97 million, -32.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CDXS stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 316.67% from the latest price.
News
Codexis Earnings Call Transcript: Q2 2026
Q2 2026 revenue reached $14.9M with improved gross margins and a narrowed net loss. The company advanced its ECO Synthesis platform, secured $25M in new financing, and is progressing on a new GMP facility. Commercial momentum is strong, with new product approvals and expanding partnerships.
Codexis Quarterly report: Q2 2026
Codexis has published its Q2 2026 quarterly earnings report on August 11, 2026.
Codexis Earnings release: Q2 2026
Codexis released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Codexis Reports Second Quarter 2026 Financial Results
Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO S...
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide ther...
Codexis to Report Second Quarter 2026 Financial Results on August 11
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today ...
Codexis 16.667M share Spot Secondary priced at $1.50
Piper Sandler and Cantor Fitzgerald acted as joint book running managers for the offering.
Codexis Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide ther...
Codexis announces common stock offering, no amount given
Codexis (CDXS) announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered…
Codexis Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide thera...
Codexis Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and an advisory vote on executive compensation, all of which were approved. A quorum was established with 82% voting power represented, and no questions were raised by stockholders.
Codexis Slides: Corporate presentation
Codexis has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Codexis reports Q1 EPS (10c), consensus (10c)
Reports Q1 revenue $15.25M, consensus $14.53M. “Next week Codexis (CDXS) will present new data at the TIDES USA annual meeting demonstrating how the ECO Synthesis Manufacturing Platform enables contro...
Codexis backs FY26 revenue view $72M-$76M, consensus $74.24M
The company said, “Codexis (CDXS) expects that its existing cash, cash equivalents, and short-term investments will be sufficient to fund its planned operations through the end of 2027.” Published fir...
Codexis Earnings Call Transcript: Q1 2026
Q1 2026 saw strong revenue growth, improved margins, and narrowed losses, driven by new partnerships and the expanding ECO Synthesis platform. The company is scaling production, advancing regulatory engagement, and expects continued momentum with robust guidance for 2026.
Codexis Earnings release: Q1 2026
Codexis released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Codexis Quarterly report: Q1 2026
Codexis has published its Q1 2026 quarterly earnings report on May 7, 2026.
Codexis Reports First Quarter 2026 Financial Results
Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis m...
Codexis to share RNA manufacturing advances at TIDES USA
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new ...
Codexis Proxy statement: Proxy filing
Codexis filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Codexis Proxy statement: Proxy filing
Codexis filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Codexis Earnings Call Transcript: Q4 2025
2025 marked a pivotal year with strong revenue growth, key commercial agreements, and technical milestones in the ECO Synthesis platform. Guidance for 2026 anticipates continued revenue growth, stable margins, and further expansion in RNA medicine manufacturing.
Codexis Annual report: Q4 2025
Codexis has published its Q4 2025 annual report on March 11, 2026.
Codexis Earnings release: Q4 2025
Codexis released its Q4 2025 earnings on March 11, 2026, summarizing the period's financial results.
Codexis reports Q4 EPS 11c, consensus (4c)
Reports Q4 revenue $38.92M, consensus $35.83M. “Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis Manufacturing Platform to customers in the RNAi indust...